A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
Public ClinicalTrials.gov record NCT04501679. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis
Study identification
- NCT ID
- NCT04501679
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Galderma R&D
- Industry
- Enrollment
- 274 participants
Conditions and interventions
Conditions
Interventions
- Nemolizumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 10, 2020
- Primary completion
- Mar 29, 2022
- Completion
- Mar 30, 2022
- Last update posted
- Jul 9, 2024
2020 – 2022
United States locations
- U.S. sites
- 22
- U.S. states
- 14
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Galderma Investigational Site | Fountain Valley | California | 92708 | — |
| Galderma Investigational Site | San Diego | California | 92123 | — |
| Galderma Investigational Site | Washington D.C. | District of Columbia | 20037 | — |
| Galderma Investigational Site | Aventura | Florida | 33180 | — |
| Galderma Investigational Site | Miami | Florida | 33136 | — |
| Galderma Investigational Site | North Miami Beach | Florida | 33162-4708 | — |
| Galderma Investigational Site | Ormond Beach | Florida | 32174 | — |
| Galderma Investigational Site | Chicago | Illinois | 60602 | — |
| Galderma Investigational Site | Indianapolis | Indiana | 46250 | — |
| Galderma Investigational Site | Louisville | Kentucky | 40241 | — |
| Galderma Investigational Site | Boston | Massachusetts | 02111 | — |
| Galderma Investigational Site | Saint Joseph | Michigan | 49085 | — |
| Galderma Investigational Site | New York | New York | 10021 | — |
| Galderma Investigational Site | Cincinnati | Ohio | 45627 | — |
| Galderma Investigational Site | Dublin | Ohio | 43016 | — |
| Galderma Investigational Site | Anderson | South Carolina | 29621 | — |
| Galderma Investigational Site | Murfreesboro | Tennessee | 37130 | — |
| Galderma Investigational Site | Dallas | Texas | 75230 | — |
| Galderma Investigational Site | Dripping Springs | Texas | 78620 | — |
| Galderma Investigational Site | Pflugerville | Texas | 78660 | — |
| Galderma Investigational Site | Webster | Texas | 77004 | — |
| Galderma Investigational Site | Morgantown | West Virginia | 26505 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04501679, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04501679 live on ClinicalTrials.gov.